Review Pending For Investigational Regimen For Hepatitis C

By Dr. Amna Sheikh   
Tuesday, 11 November 2014 11:27

This article is for premium subscriber only.

Read more...
 

Another Company Gets Another Chance For A New Drug Application

By Dr. Amna Sheikh   
Tuesday, 11 November 2014 10:20

This article is for premium subscriber only.

Read more...
 

The New Drug Application is Actually Supported With 2 Fundamental Phase Three Experimental Trials

By Dr. Amna Sheikh   
Tuesday, 11 November 2014 10:14

This article is for premium subscriber only.

Read more...
 

PDUFA Date Approaching

By Dr. Amna Sheikh   
Tuesday, 11 November 2014 09:05

 This article is for premium subscriber only.    .
Read more...
 

Going to the Next Stage in Revenues

By David Fowler   
Wednesday, 05 November 2014 06:00
This article is for premium subscriber only.
Read more...
 

Muscle and Tendon Regeneration Will Revolutionize Sports Medicine

By Ray Dirks   
Thursday, 16 October 2014 15:40
This trade thesis is being presented to premium subscriber only.
Read more...
 

What's Next: Investors Place Ebola Pandemic Stock Bets

By M.E.Garza   
Monday, 06 October 2014 15:22

This trade thesis  is being presented to premium subscribers only.

Read more...
 

Bottom bouncer with quick trade profit potential

By David Ibrahim   
Friday, 03 October 2014 07:31

This trade idea is being presented to premium subscribers only.

Read more...
 

Phase IIb Study Results Expected this Quarter

By M.E.Garza   
Tuesday, 30 September 2014 07:27
icon_tradethesisThis trade idea is being posted for premium subscribers first.
Read more...
 

Promising with interim data coming, but should you buy?

By William Kent   
Thursday, 25 September 2014 13:37
Prostate cancer is the most common cancer among men in the United States.
Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 56

Newsletter

BioMedReports U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks... http://t.co/32TdXZ0uSX
2hreplyretweetfavorite
BioMedReports Aratana Therapeutics Inc (NASDAQ:PETX) Hits 5-Month High On Positive development: After the announcement of p... http://t.co/xsLwjGgVSe
BioMedReports Doug Loe: Canada Has Earned Its Spot in the Biotech All-Star Team Photo: Biotech investors in the United State... http://t.co/TQiDczlMjS
Benzinga.com supporter Seeking Alpha Certified